BUDESONIDE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Orodispersible tablets 1mg (specialist initiation: for eosinophilic oesophagitis)

Dosage:

Dosing as per BNF

As per SMC 2158: Treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age).
SMC restriction: For patients unsuccessfully treated with proton pump inhibitors. 

Important: Formulation and dosage details

Formulation:

Rectal foam 2mg/dose

Dosage:

As per SMC 409/07: treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon. 

PREDNISOLONE

Important: Therapy notes

MHRA advice: Drug-name confusion: reminder to be vigilant for potential errors (January 2018) (www.gov.uk).

  • Note:  Use standard prednisolone tablets instead of enteric-coated tablets in inflammatory bowel disease.
  • Note: Consider co-prescribing bone protection for the duration of steroid therapy, refer to Drugs affecting bone metabolism.

Important: Formulation and dosage details

Formulation:

Tablets 1mg, 5mg

Important: Formulation and dosage details

Formulation:

Soluble tablets 5mg

Important: Formulation and dosage details

Formulation:

Suppositories 5mg

Editorial Information

Last reviewed: 24/06/2021

Document Id: F226